Your browser is no longer supported. Please, upgrade your browser.
AMGN [NASD]
Amgen Inc.
IndexDJIA S&P500 P/E21.22 EPS (ttm)9.84 Insider Own0.20% Shs Outstand573.00M Perf Week0.92%
Market Cap118.36B Forward P/E11.67 EPS next Y17.88 Insider Trans-0.33% Shs Float566.76M Perf Month-2.08%
Income5.75B PEG3.55 EPS next Q4.26 Inst Own78.00% Short Float1.95% Perf Quarter-14.56%
Sales25.48B P/S4.64 EPS this Y-4.40% Inst Trans0.08% Short Ratio4.36 Perf Half Y-11.84%
Book/sh14.39 P/B14.50 EPS next Y8.89% ROA9.20% Target Price249.71 Perf Year-7.21%
Cash/sh14.25 P/C14.64 EPS next 5Y5.97% ROE60.60% 52W Range200.47 - 276.69 Perf YTD-9.24%
Dividend7.04 P/FCF23.65 EPS past 5Y6.30% ROI19.50% 52W High-24.58% Beta0.62
Dividend %3.37% Quick Ratio1.00 Sales past 5Y3.30% Gross Margin75.30% 52W Low4.10% ATR3.55
Employees24300 Current Ratio1.30 Sales Q/Q5.20% Oper. Margin29.10% RSI (14)45.86 Volatility1.46% 1.74%
OptionableYes Debt/Eq3.98 EPS Q/Q-73.60% Profit Margin22.50% Rel Volume0.64 Prev Close207.63
ShortableYes LT Debt/Eq3.45 EarningsNov 02 AMC Payout67.90% Avg Volume2.54M Price208.68
Recom2.50 SMA20-0.09% SMA50-3.39% SMA200-11.50% Volume1,622,926 Change0.51%
Sep-23-21Downgrade Daiwa Securities Outperform → Neutral $220
Sep-07-21Downgrade Morgan Stanley Overweight → Equal-Weight $280 → $251
Dec-29-20Initiated Daiwa Securities Buy $300
Oct-28-20Initiated UBS Neutral $232
Oct-26-20Upgrade Raymond James Mkt Perform → Outperform $255
Oct-12-20Upgrade Truist Hold → Buy
Oct-09-20Downgrade Truist Buy → Hold $251
Oct-09-20Downgrade Bernstein Outperform → Mkt Perform
Oct-08-20Downgrade Raymond James Outperform → Mkt Perform
Apr-15-20Resumed Guggenheim Neutral
Mar-31-20Initiated Wolfe Research Peer Perform
Mar-30-20Upgrade Raymond James Mkt Perform → Outperform $255
Mar-05-20Upgrade BofA/Merrill Neutral → Buy $245 → $250
Feb-27-20Initiated Barclays Equal Weight $235
Jan-31-20Downgrade Robert W. Baird Neutral → Underperform $173 → $185
Jan-21-20Upgrade Evercore ISI In-line → Outperform
Dec-24-19Initiated Raymond James Mkt Perform
Dec-17-19Resumed Morgan Stanley Overweight $280
Nov-12-19Initiated SunTrust Buy $256
Nov-05-19Upgrade Cantor Fitzgerald Neutral → Overweight $230 → $255
Oct-26-21 04:00PM  
03:02PM  
Oct-25-21 05:50PM  
Oct-21-21 04:00PM  
Oct-20-21 01:27PM  
10:32AM  
08:46AM  
Oct-19-21 05:50PM  
09:17AM  
Oct-18-21 07:30AM  
Oct-13-21 06:14AM  
Oct-08-21 12:03PM  
08:08AM  
05:36AM  
Oct-07-21 12:51PM  
10:53AM  
09:00AM  
08:48AM  
06:30AM  
06:30AM  
06:30AM  
Oct-06-21 09:30AM  
Oct-05-21 08:50AM  
Oct-04-21 04:00PM  
11:41AM  
Oct-02-21 06:00AM  
Sep-29-21 05:00PM  
07:14AM  
Sep-28-21 10:11AM  
09:15AM  
Sep-27-21 10:18AM  
06:00AM  
Sep-24-21 08:09PM  
Sep-22-21 04:00PM  
09:00AM  
06:10AM  
Sep-20-21 07:02PM  
04:09PM  
03:49PM  
Sep-19-21 09:47AM  
Sep-16-21 08:17AM  
08:08AM  
04:30AM  
Sep-14-21 04:00PM  
Sep-13-21 04:15PM  
04:00PM  
09:00AM  
Sep-11-21 07:05AM  
Sep-09-21 07:01PM  
05:00PM  
07:19AM  
06:29AM  
Sep-08-21 04:00PM  
08:31AM  
Sep-07-21 04:22PM  
04:00PM  
02:40PM  
12:18PM  
11:29AM  
10:23AM  
08:28AM  
Sep-05-21 07:15AM  
Sep-03-21 04:00PM  
Sep-02-21 05:50PM  
11:31AM  
08:00AM  
Aug-30-21 10:16AM  
Aug-27-21 12:11PM  
04:30AM  
Aug-19-21 03:56PM  
Aug-12-21 03:00PM  
Aug-11-21 07:55AM  
Aug-09-21 04:28PM  
Aug-06-21 01:43PM  
Aug-05-21 04:25PM  
01:59PM  
05:48AM  
Aug-04-21 04:16PM  
03:30PM  
02:44PM  
12:15PM  
10:30AM  
09:52AM  
04:12AM  
Aug-03-21 10:31PM  
06:09PM  
05:15PM  
04:34PM  
04:31PM  
04:20PM  
04:07PM  
04:01PM  
12:40PM  
Aug-02-21 05:21PM  
09:36AM  
Aug-01-21 10:32AM  
Jul-30-21 04:00PM  
12:31PM  
11:21AM  
Jul-29-21 07:10PM  
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behcet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SUGAR RONALD DDirectorMay 12Option Exercise71.641,00071,64016,927May 12 08:11 PM
SUGAR RONALD DDirectorMay 12Sale250.591,000250,59015,927May 12 08:11 PM
Grygiel Nancy A.SVP & CCOMay 11Option Exercise162.602,500406,50014,961May 12 08:10 PM
Grygiel Nancy A.SVP & CCOMay 11Sale252.512,500631,27212,461May 12 08:10 PM
Williams R SandersDirectorMay 07Sale251.7825062,9454,409May 10 06:38 PM
SUGAR RONALD DDirectorApr 14Option Exercise71.641,00071,64016,927Apr 15 06:27 PM
SUGAR RONALD DDirectorApr 14Sale249.981,000249,98015,927Apr 15 06:27 PM
SUGAR RONALD DDirectorMar 10Option Exercise71.641,00071,64016,805Mar 10 06:07 PM
SUGAR RONALD DDirectorMar 10Sale231.531,000231,53015,805Mar 10 06:07 PM
Bradway Robert AChairman, CEO and PresidentFeb 18Option Exercise54.6973,5004,019,715618,380Feb 22 07:27 PM
REESE DAVID MEVP, Research and DevelopmentFeb 16Option Exercise54.692,300125,78742,059Feb 16 08:59 PM
SUGAR RONALD DDirectorFeb 10Option Exercise71.641,00071,64016,805Feb 10 07:40 PM
SUGAR RONALD DDirectorFeb 10Sale238.401,000238,40015,805Feb 10 07:40 PM
Williams R SandersDirectorFeb 08Sale237.9925059,4984,659Feb 08 08:36 PM
Graham Jonathan PEVP, Gen. Counsel & Secy.Feb 04Sale236.5111,1102,627,62539,945Feb 05 08:06 PM
SUGAR RONALD DDirectorJan 13Option Exercise71.641,00071,64016,805Jan 14 06:25 PM
SUGAR RONALD DDirectorJan 13Sale235.991,000235,99015,805Jan 14 06:25 PM
Williams R SandersDirectorNov 09Sale242.4025060,6004,909Nov 10 06:32 PM